Daihan Pharmaceutical Co.,Ltd. (KOSDAQ:023910)
25,400
+150 (0.59%)
Last updated: Apr 1, 2025
Daihan Pharmaceutical Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
Operating Revenue | 204,195 | 195,911 | 184,268 | 171,463 | 166,080 | Upgrade
|
Other Revenue | - | - | - | -0 | - | Upgrade
|
Revenue | 204,195 | 195,911 | 184,268 | 171,463 | 166,080 | Upgrade
|
Revenue Growth (YoY) | 4.23% | 6.32% | 7.47% | 3.24% | -1.59% | Upgrade
|
Cost of Revenue | 134,788 | 130,599 | 124,455 | 115,781 | 109,885 | Upgrade
|
Gross Profit | 69,407 | 65,312 | 59,812 | 55,682 | 56,195 | Upgrade
|
Selling, General & Admin | 28,428 | 26,945 | 25,445 | 24,923 | 24,892 | Upgrade
|
Research & Development | 1,802 | 1,641 | 567.87 | 790.59 | 689.17 | Upgrade
|
Other Operating Expenses | 479.63 | 411.75 | 387.26 | 334.4 | 303.68 | Upgrade
|
Operating Expenses | 31,327 | 29,517 | 26,844 | 26,614 | 26,232 | Upgrade
|
Operating Income | 38,081 | 35,795 | 32,968 | 29,068 | 29,963 | Upgrade
|
Interest Expense | -1.81 | -52.47 | -593.43 | -469.27 | -617.06 | Upgrade
|
Interest & Investment Income | 1,475 | 87.18 | 486.66 | 506.7 | 421.05 | Upgrade
|
Currency Exchange Gain (Loss) | 1,229 | 504.71 | 525.35 | 687.03 | -426.96 | Upgrade
|
Other Non Operating Income (Expenses) | 1,184 | 87.57 | 73.92 | 599.56 | 822.93 | Upgrade
|
EBT Excluding Unusual Items | 41,967 | 36,422 | 33,461 | 30,392 | 30,163 | Upgrade
|
Gain (Loss) on Sale of Investments | 303.6 | 288.69 | - | - | - | Upgrade
|
Gain (Loss) on Sale of Assets | 58.03 | 22.53 | -9.4 | 41.28 | 19.72 | Upgrade
|
Asset Writedown | - | - | - | - | -7,650 | Upgrade
|
Pretax Income | 42,329 | 36,734 | 33,451 | 30,433 | 22,532 | Upgrade
|
Income Tax Expense | 8,569 | 8,307 | 8,491 | 7,763 | 5,151 | Upgrade
|
Net Income | 33,759 | 28,426 | 24,961 | 22,670 | 17,381 | Upgrade
|
Net Income to Common | 33,759 | 28,426 | 24,961 | 22,670 | 17,381 | Upgrade
|
Net Income Growth | 18.76% | 13.88% | 10.10% | 30.43% | -38.29% | Upgrade
|
Shares Outstanding (Basic) | 6 | 6 | 6 | 6 | 6 | Upgrade
|
Shares Outstanding (Diluted) | 6 | 6 | 6 | 6 | 6 | Upgrade
|
Shares Change (YoY) | -0.00% | -1.74% | -0.27% | 0.02% | -0.02% | Upgrade
|
EPS (Basic) | 5741.00 | 4834.00 | 4171.00 | 3778.00 | 2897.00 | Upgrade
|
EPS (Diluted) | 5741.00 | 4834.00 | 4171.00 | 3778.00 | 2897.00 | Upgrade
|
EPS Growth | 18.76% | 15.90% | 10.40% | 30.41% | -38.28% | Upgrade
|
Free Cash Flow | 19,841 | 17,580 | 20,378 | 28,767 | 28,267 | Upgrade
|
Free Cash Flow Per Share | 3374.18 | 2989.54 | 3405.28 | 4794.06 | 4711.52 | Upgrade
|
Gross Margin | 33.99% | 33.34% | 32.46% | 32.48% | 33.84% | Upgrade
|
Operating Margin | 18.65% | 18.27% | 17.89% | 16.95% | 18.04% | Upgrade
|
Profit Margin | 16.53% | 14.51% | 13.55% | 13.22% | 10.46% | Upgrade
|
Free Cash Flow Margin | 9.72% | 8.97% | 11.06% | 16.78% | 17.02% | Upgrade
|
EBITDA | 45,362 | 44,459 | 42,176 | 40,479 | 41,263 | Upgrade
|
EBITDA Margin | 22.21% | 22.69% | 22.89% | 23.61% | 24.85% | Upgrade
|
D&A For EBITDA | 7,282 | 8,663 | 9,208 | 11,411 | 11,300 | Upgrade
|
EBIT | 38,081 | 35,795 | 32,968 | 29,068 | 29,963 | Upgrade
|
EBIT Margin | 18.65% | 18.27% | 17.89% | 16.95% | 18.04% | Upgrade
|
Effective Tax Rate | 20.24% | 22.61% | 25.38% | 25.51% | 22.86% | Upgrade
|
Advertising Expenses | 99.76 | 78.69 | 93.67 | 63.18 | 48.89 | Upgrade
|
Updated Mar 1, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.